Ultrasound Guided QLB III Versus Intrathecal Morphine for Analgesia After Cesarean Section

Overview

Subarachnoid morphine (SAM) is the gold standard for treating postoperative pain after cesarean delivery (CD) but it has undesirable side effects, that's why the aim of our study is to identify whether ultrasound-guided Quadratus lumborum block type 3, a new regional anesthetic technique that blocks the abdominal wall neural afferents, can provide at the same time better postoperative analgesia after CD with less side effects

Full Title of Study: “Ultrasound Guided Quadratus Lumborum Type III Block Versus Intrathecal Morphine for Analgesia After Cesarean Delivery”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: September 30, 2017

Detailed Description

In this prospective double blinded randomized study,120 parturients undergoing cesarian delivery via a Pfannenstiel incision and who agreed to spinal anesthesia were randomly scheduled to receive either a SAM (group SAM, n=60) or a Quadratus lumborum block type 3 (group QLB, n=60).Spinal anesthesia was initiated with hyperbaric Bupivacaïne 0.5% 10 mg, 0,005 mg SUFENTANIL MEDIS and 0.1 mg morphine in the SAM group and with Bupivacaïne 0.5% 10 mg, 0,005 mg SUFENTANIL MEDIS and 1 ml normal saline in group QLB. After surgery, bilateral QLB block type 3 was performed with the patient in lateral position using bupivacaine 0.25% , 20 mL on each side in group QLB and 20 ml normal saline in group SAM. Postoperative analgesia for the first 24 hours consisted of a patient controlled analgesia with IV morphine only. If necessary breakthrough pain was treated by 01 g paracetamol intravenously by the same doctor in charge of taking the values of the visual analogue scale. Patients were assessed postoperatively in the postanesthesia care unit (time 0 hours) and at 2, 4, 6, 12 and 24 hours. Visual analogue scale (VAS) for pain at rest and during the palpation of the uterine globe was noted. The primary outcome measure was the total dose of morphine over 24 hours delivered by a patient-controlled analgesia system at predetermined intervals. Secondary outcomes were visual analogue scale (VAS) for pain at rest and on the palpation of the uterine globe ,heart rate, blood pressure, itching, nausea, pruritus, vomiting and sedation.

Interventions

  • Drug: Morphine
    • spinal morphine is done before cesarean section
  • Drug: Quadratus lumborum block
    • a US Block QLB is done after surgery

Arms, Groups and Cohorts

  • Active Comparator: spinal morphine
    • intrathecal morphine with 10 mg bupivacaine, 5 gamma sufenta and 100 gamma morphine. Intervention: In the end of surgery a QLB block is done with 20 ml of normal saline per side.
  • Active Comparator: quadratus lumborum block
    • intrathecal anesthesia with10 mg bupivacaine, 5 gamma sufena and 1 ml normal saline. Procedure : a quadratus lumborum block is done with 20 ml of bupivacaine 0,125% per side.

Clinical Trial Outcome Measures

Primary Measures

  • Total morphine consumption over 24 hours postoperatively
    • Time Frame: Arrival to post anesthesia care unit until 24 hours posteratively
    • Total IV morphine used when started postoperatively using a PCA with morphine in the post anesthesia care unit until 2′ hours posteratively.

Secondary Measures

  • Time to first analgesic demand using PCA pump with morphine
    • Time Frame: Arrival to post anesthesia care unit until 24 hours posteratively
    • recording the exact time to first analgesic demand by using the PCA with Morphine
  • Visual analog scale (VAS) pain scores at rest and during the palpation of the uterine globe
    • Time Frame: Arrival to post anesthesia care unit until 24 hours posteratively
    • At predetermined intervalls, visual analog scale (VAS) pain scores at rest and at the palpation of the uterine globe were noted.
  • Time to first deambulaton after surgery
    • Time Frame: Arrival to post anesthesia care unit until 24 hours posteratively
    • After surgery, time when the patient was able to move from bed was noted.

Participating in This Clinical Trial

Inclusion Criteria

  • ASA I/II. – Normal singleton pregnancy with a gestation of at least 37 weeks. Exclusion Criteria:

  • Heart disease – Coagulopathy – pre-eclampsia – BMI> 40 – Patient refusal to undergo the Quadratus lumborum block. – Allergy to local anesthetics

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University Tunis El Manar
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ben marzouk Sofiene, MD, assistant professor – University Tunis El Manar
  • Overall Official(s)
    • Hayene Maghrebi, Professor, Study Chair, tunis maternity center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.